ReviewClinical pharmacokinetics2021
Clinical Pharmacokinetics of Daptomycin.
Review in Clinical pharmacokinetics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 44 citations in OpenAlex.
- Updated antimicrobial dosing recommendations for obese patients.Antimicrobial agents and chemotherapy · 2024Pooled it
- Comprehensive pharmacokinetic/pharmacodynamic analysis of commercially available premixed daptomycin preparations againstJAC-antimicrobial resistance · 2026Article
- Linezolid-resistant and vancomycin-resistantASM case reports · 2026Article
- A pharmacovigilance study of daptomycin use in infants under 1 year old based on the FDA adverse event reporting system.Scientific reports · 2025Article
- Synergistic antibacterial activity and prevention of drug resistance of daptomycin combined with fosfomycin against methicillin-resistantAntimicrobial agents and chemotherapy · 2025Article
- Use of Daptomycin to Manage Severe MRSA Infections in Humans.Antibiotics (Basel, Switzerland) · 2025Review
- Advancing systemic toxicity risk assessment: Evaluation of a NAM-based toolbox approach.Toxicological sciences : an official journal of the Society of Toxicology · 2025Article
- PK/PD-Guided Strategies for Appropriate Antibiotic Use in the Era of Antimicrobial Resistance.Antibiotics (Basel, Switzerland) · 2025Review
- An Engineered Nisin Analogue with a Hydrophobic Moiety Attached at Position 17 Selectively InhibitsACS chemical biology · 2024Article
- A machine learning approach to predict daptomycin exposure from two concentrations based on Monte Carlo simulations.Antimicrobial agents and chemotherapy · 2024Article
- Antimicrobial Peptides towards Clinical Application-A Long History to Be Concluded.International journal of molecular sciences · 2024Review
- Removal of common antimicrobial agents by sustained low-efficiency dialysis.Antimicrobial agents and chemotherapy · 2024Article
- Optimizing Antibiotic Therapy for Intravenous Drug Users: A Narrative Review Unraveling Pharmacokinetics/Pharmacodynamics Challenges.European journal of drug metabolism and pharmacokinetics · 2024Review
- Patients with Obesity Should be Recognised as a Special Patient Population During Drug Development of Antibacterial and Antifungal Agents; A Call to Action.Clinical pharmacokinetics · 2024Article
- Population pharmacokinetics of intravenous daptomycin in critically ill patients: implications for selection of dosage regimens.Frontiers in pharmacology · 2024Article
- Structure-activity relationships of antibacterial peptides.Microbial biotechnology · 2023Review
- Population Pharmacokinetic Model for Unbound Concentrations of Daptomycin in Patients with MRSA Including Patients Undergoing Hemodialysis.European journal of drug metabolism and pharmacokinetics · 2023Article
- When and How to Use MIC in Clinical Practice?Antibiotics (Basel, Switzerland) · 2022Review
- Population Pharmacokinetic/Pharmacodynamic Modelling of Daptomycin for Schedule Optimization in Patients with Renal Impairment.Pharmaceutics · 2022Article
- Role of Daptomycin in Cutaneous Wound Healing: A Narrative Review.Antibiotics (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Due to the low level of resistance observed with daptomycin, this antibiotic has an important place in the treatment of severe Gram-positive infections. It is the first-in-class of the group of calcium-dependent, membrane-binding lipopeptides, and is a cyclic peptide constituted of 13 amino acids and an n-decanoyl fatty acid chain. The antibacterial action of daptomycin requires its complexation with calcium. Daptomycin is not absorbed from the gastrointestinal tract and needs to be administered parenterally. The distribution of daptomycin is limited (volume of distribution of 0.1 L/kg in healthy volunteers) due to its negative charge at physiological pH and its high binding to plasma proteins (about 90%). Its elimination is mainly renal, with about 50% of the dose excreted unchanged in the urine, justifying dosage adjustment for patients with renal insufficiency. The pharmacokinetics of daptomycin are altered under certain pathophysiological conditions, resulting in high interindividual variability. As a result, therapeutic drug monitoring of daptomycin may be of interest for certain patients, such as intensive care unit patients, patients with renal or hepatic insufficiency, dialysis patients, obese patients, or children. A target for the ratio of the area under the curve to the minimum inhibitory concentration > 666 is usually recommended for clinical efficacy, whereas in order to limit the risk of undesirable muscular effects the residual concentration should not exceed 24.3 mg/L.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.